David Olmos, MBBS, MSc, PhD, discusses research presented at the ASCO 2023 Annual Meeting assessing outcomes with first-line novel hormonal therapy or taxane therapy in metastatic castration-resistant prostate cancer based on patients' BRCA/HRR status.
Dr. David Olmos, MBBS, MSc, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, discusses 2023 ASCO Annual Meeting abstract 5003, “Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first‑line (1L) treatment stratified by BRCA status.”
We are reporting the initial results of the first cohort which included 729 patients with metastatic castration-resistant prostate cancer who initiated treatment in the first-line setting with novel hormonal therapy or taxane. We collected prospective data for these patients.
We analyzed in parallel the germline DNA and the somatic DNA to establish the mutational status of 11 genes related to homologous recombination repair (HRR). Our main analysis focused on stratifying outcomes of patients according to BRCA status—BRCA1 or BRCA 2 alterations.
The initial results suggest that BRCA patients, independently of the somatic or germline origin of the mutation or having a biallelic or monoallelic alteration, as well as independently of the first-line treatment choice, have shorter radiographic progression-free survival (PFS), PFS2, and overall survival, than the total non-BRCA patient population and worse outcomes than the non-BRCA patients in the HRR subgroup. Additionally, patients with non-BRCA HRR alterations had worse outcomes than patients without mutations.
Transcript has been edited for clarity.